Literature DB >> 9232728

Pharmacological therapy of Helicobacter pylori infection.

J S Hoffman1.   

Abstract

Helicobacter pylori has been associated with several diseases including peptic ulcer disease and gastric cancer. Eradication of H pylori not only results in ulcer healing, but reduces recurrences essentially curing peptic ulcer disease. Eradicating H pylori can be difficult. There are several reasons for antimicrobial failure, and the resistance rates for several antibiotics are increasing. The most common drugs used to treat this infection include amoxicillin, clarithromycin, tetracycline, bismuth, and omeprazole and lansoprazole. Dual therapy using a proton pump inhibitor and a single antibiotic gives a suboptimal eradication rate. Triple therapy using at least two antibiotics and either bismuth or a proton pump inhibitor gives satisfactory eradication rates of 90%. However, these regimens are complicated and have significant side effects and compliance problems. The ideal regimen has yet to be developed. In the future, we will prevent infection with immunization. Several vaccines are being developed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9232728

Source DB:  PubMed          Journal:  Semin Gastrointest Dis        ISSN: 1049-5118


  7 in total

1.  Esomeprazole: a review of its use in the management of acid-related disorders in the US.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Irigenin, a novel lead from Iris confusa for management of Helicobacter pylori infection with selective COX-2 and HpIMPDH inhibitory potential.

Authors:  Passent M Abdel-Baki; Moshera M El-Sherei; Amal E Khaleel; Marwa M Abdel-Aziz; Mona M Okba
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

Review 4.  Esomeprazole: a review of its use in the management of acid-related disorders.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

6.  Chitosan Inhibits Helicobacter pylori Growth and Urease Production and Prevents Its Infection of Human Gastric Carcinoma Cells.

Authors:  Shun-Hsien Chang; Pei-Ling Hsieh; Guo-Jane Tsai
Journal:  Mar Drugs       Date:  2020-10-29       Impact factor: 5.118

7.  Anti-Helicobacter pylori activity and immunostimulatory effect of extracts from Byrsonima crassa Nied. (Malpighiaceae).

Authors:  Cibele Bonacorsi; Maria Stella G Raddi; Iracilda Z Carlos; Miriam Sannomiya; Wagner Vilegas
Journal:  BMC Complement Altern Med       Date:  2009-01-16       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.